Literature DB >> 28330852

A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice.

Abudukadier Abulizi1, Rachel J Perry1, João Paulo G Camporez1, Michael J Jurczak1, Kitt Falk Petersen1, Patricia Aspichueta1,2,3, Gerald I Shulman4,5,6.   

Abstract

Lipodystrophy is a rare disorder characterized by complete or partial loss of adipose tissue. Patients with lipodystrophy exhibit hypertriglyceridemia, severe insulin resistance, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). Efforts to ameliorate NASH in lipodystrophies with pharmacologic agents have met with limited success. We examined whether a controlled-release mitochondrial protonophore (CRMP) that produces mild liver-targeted mitochondrial uncoupling could decrease hypertriglyceridemia and reverse NASH and diabetes in a mouse model (fatless AZIP/F-1 mice) of severe lipodystrophy and diabetes. After 4 wk of oral CRMP (2 mg/kg body weight per day) or vehicle treatment, mice underwent hyperinsulinemic-euglycemic clamps combined with radiolabeled glucose to assess liver and muscle insulin responsiveness and tissue lipid measurements. CRMP treatment reversed hypertriglyceridemia and insulin resistance in liver and skeletal muscle. Reversal of insulin resistance could be attributed to reductions in diacylglycerol content and reduced PKC-ε and PKC-θ activity in liver and muscle respectively. CRMP treatment also reversed NASH as reflected by reductions in plasma aspartate aminotransferase and alanine aminotransferase concentrations; hepatic steatosis; and hepatic expression of IL-1α, -β, -2, -4, -6, -10, -12, CD69, and caspase 3 and attenuated activation of the IRE-1α branch of the unfolded protein response. Taken together, these results provide proof of concept for the development of liver-targeted mitochondrial uncoupling agents as a potential novel therapy for lipodystrophy-associated hypertriglyceridemia, NASH and diabetes.-Abulizi, A., Perry, R. J., Camporez, J. P. G., Jurczak, M. J., Petersen, K. F., Aspichueta, P., Shulman, G. I. A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice. © FASEB.

Entities:  

Keywords:  NAFLD; NASH; insulin resistance; mitochondrial uncoupling; type 2 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28330852      PMCID: PMC5471523          DOI: 10.1096/fj.201700001R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  32 in total

1.  Translational control is required for the unfolded protein response and in vivo glucose homeostasis.

Authors:  D Scheuner; B Song; E McEwen; C Liu; R Laybutt; P Gillespie; T Saunders; S Bonner-Weir; R J Kaufman
Journal:  Mol Cell       Date:  2001-06       Impact factor: 17.970

2.  Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats.

Authors:  Rachel J Perry; Dongyan Zhang; Xian-Man Zhang; James L Boyer; Gerald I Shulman
Journal:  Science       Date:  2015-02-26       Impact factor: 47.728

3.  Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle.

Authors:  Chunli Yu; Yan Chen; Gary W Cline; Dongyan Zhang; Haihong Zong; Yanlin Wang; Raynald Bergeron; Jason K Kim; Samuel W Cushman; Gregory J Cooney; Bronwyn Atcheson; Morris F White; Edward W Kraegen; Gerald I Shulman
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

4.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

5.  Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease.

Authors:  Varman T Samuel; Zhen-Xiang Liu; Amy Wang; Sara A Beddow; John G Geisler; Mario Kahn; Xian-man Zhang; Brett P Monia; Sanjay Bhanot; Gerald I Shulman
Journal:  J Clin Invest       Date:  2007-02-22       Impact factor: 14.808

Review 6.  From endoplasmic-reticulum stress to the inflammatory response.

Authors:  Kezhong Zhang; Randal J Kaufman
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

7.  Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans.

Authors:  Julia Szendroedi; Toru Yoshimura; Esther Phielix; Chrysi Koliaki; Mellissa Marcucci; Dongyan Zhang; Tomas Jelenik; Janette Müller; Christian Herder; Peter Nowotny; Gerald I Shulman; Michael Roden
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-16       Impact factor: 11.205

8.  Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease.

Authors:  Puneet Puri; Faridoddin Mirshahi; Onpan Cheung; Ramesh Natarajan; James W Maher; John M Kellum; Arun J Sanyal
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

9.  Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

Authors:  Varman T Samuel; Zhen-Xiang Liu; Xianqin Qu; Benjamin D Elder; Stefan Bilz; Douglas Befroy; Anthony J Romanelli; Gerald I Shulman
Journal:  J Biol Chem       Date:  2004-05-27       Impact factor: 5.157

10.  Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice.

Authors:  Michael J Jurczak; Ann-Hwee Lee; Francois R Jornayvaz; Hui-Young Lee; Andreas L Birkenfeld; Blas A Guigni; Mario Kahn; Varman T Samuel; Laurie H Glimcher; Gerald I Shulman
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

View more
  22 in total

1.  Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes.

Authors:  Leigh Goedeke; Rachel J Perry; Gerald I Shulman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

Review 2.  Use the Protonmotive Force: Mitochondrial Uncoupling and Reactive Oxygen Species.

Authors:  Brandon J Berry; Adam J Trewin; Andrea M Amitrano; Minsoo Kim; Andrew P Wojtovich
Journal:  J Mol Biol       Date:  2018-04-04       Impact factor: 5.469

3.  Ectopic lipid deposition mediates insulin resistance in adipose specific 11β-hydroxysteroid dehydrogenase type 1 transgenic mice.

Authors:  Abudukadier Abulizi; João-Paulo Camporez; Dongyan Zhang; Varman T Samuel; Gerald I Shulman; Daniel F Vatner
Journal:  Metabolism       Date:  2018-12-19       Impact factor: 8.694

Review 4.  Mechanisms of Insulin Action and Insulin Resistance.

Authors:  Max C Petersen; Gerald I Shulman
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

5.  [1,2,5]Oxadiazolo[3,4-b]pyrazine-5,6-diamine Derivatives as Mitochondrial Uncouplers for the Potential Treatment of Nonalcoholic Steatohepatitis.

Authors:  Elizabeth S Childress; Joseph M Salamoun; Stefan R Hargett; Stephanie J Alexopoulos; Sing-Young Chen; Divya P Shah; José Santiago-Rivera; Christopher J Garcia; Yumin Dai; Simon P Tucker; Kyle L Hoehn; Webster L Santos
Journal:  J Med Chem       Date:  2020-02-17       Impact factor: 7.446

6.  Anti-inflammatory effects of oestrogen mediate the sexual dimorphic response to lipid-induced insulin resistance.

Authors:  João Paulo Camporez; Kun Lyu; Emily L Goldberg; Dongyan Zhang; Gary W Cline; Michael J Jurczak; Vishwa Deep Dixit; Kitt Falk Petersen; Gerald I Shulman
Journal:  J Physiol       Date:  2019-07-04       Impact factor: 5.182

7.  A Membrane-Bound Diacylglycerol Species Induces PKCϵ-Mediated Hepatic Insulin Resistance.

Authors:  Kun Lyu; Ye Zhang; Dongyan Zhang; Mario Kahn; Kasper W Ter Horst; Marcos R S Rodrigues; Rafael C Gaspar; Sandro M Hirabara; Panu K Luukkonen; Seohyuk Lee; Sanjay Bhanot; Jesse Rinehart; Niels Blume; Morten Grønbech Rasch; Mireille J Serlie; Jonathan S Bogan; Gary W Cline; Varman T Samuel; Gerald I Shulman
Journal:  Cell Metab       Date:  2020-09-02       Impact factor: 27.287

8.  Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates.

Authors:  Leigh Goedeke; Liang Peng; Valle Montalvo-Romeral; Gina M Butrico; Sylvie Dufour; Xian-Man Zhang; Rachel J Perry; Gary W Cline; Paul Kievit; Keefe Chng; Kitt Falk Petersen; Gerald I Shulman
Journal:  Sci Transl Med       Date:  2019-10-02       Impact factor: 17.956

9.  Novel Strategies to Treat Hepatic Steatosis and Steatohepatitis.

Authors:  Rachel J Perry
Journal:  Obesity (Silver Spring)       Date:  2019-07-25       Impact factor: 5.002

Review 10.  GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).

Authors:  Naim Alkhouri; Eric Lawitz; Mazen Noureddin; Ralph DeFronzo; Gerald I Shulman
Journal:  Expert Opin Investig Drugs       Date:  2019-09-19       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.